Abstract:Background Monovalent Omicron XBB.1.5-containing vaccines were approved for Coronavirus disease 2019 (COVID-19) 2023-2024 immunizations. Methods This ongoing, open-label, phase 2/3 study evaluated mRNA-1273.815-monovalent (50-μg Omicron XBB.1.5-spike mRNA) and mRNA-1273.231-bivalent (25-μg each Omicron XBB.1.5- and BA.4/BA.5-spike mRNAs))vaccines, administered as 5th doses to adults who previously received a primary series, a 3rd dose of an original mRNA COVID-19 vaccine, and a 4th dose of an Omicron BA.4/BA.5 bivalent vaccine. Interim safety and immunogenicity results 29 days post-vaccination are reported. Results Participants (randomized 1:1) received 50-μg mRNA-1273.815(n=50) or mRNA-1273.231(n=51); median (interquartile range) months from the prior BA.4/BA.5-bivalent dose were 8.2 (8.1-8.3) and 8.3 (8.1-8.4), respectively. Neutralizing antibody (nAb) increased from pre-booster levels against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants tested. Day 29 nAb fold-increases from pre-booster levels were numerically higher against XBB.1.5, XBB.1.16, EG.5.1, BA.2.86, and JN.1 than BA.4/BA.5, BQ.1.1 and D614G. The monovalent vaccine also cross-neutralized FL.1.5.1, EG.5.1, BA.2.86, HK.3.1, HV.1 and JN.1 variants in a participant (n=20) subset, 15 days post-vaccination. Reactogenicity was similar to previously reported mRNA-1273 original and bivalent vaccines. Conclusions XBB.1.5-containing mRNA-1273 vaccines elicit robust, diverse nAb responses against more recent SARS-CoV-2 variants including JN.1, supporting the XBB.1.5-spike sequence selection for the 2023-2024 COVID-19 vaccine update.

Correction to: Interim Report of the Reactogenicity and Immunogenicity of Severe Acute Respiratory Syndrome Coronavirus 2 XBB–Containing Vaccines

Corrigendum: Brief research report: impact of vaccination on antibody responses and mortality from severe COVID-19

Erratum: Correction of Figure in the Article "Viral, Immunologic, and Laboratory Parameters in Patients With and Without Post-Acute Sequelae of SARS-CoV-2 Infection (PASC)"

Correction: Huang et al. Next Generation of Computationally Optimized Broadly Reactive HA Vaccines Elicited Cross-Reactive Immune Responses and Provided Protection against H1N1 Virus Infection. Vaccines 2021, 9, 793

Corrigendum to: Chloro-s-triazenes-toxicokinetic, Toxicodynamic, Human Exposure, and Regulatory Considerations

Corrigendum to Antibody Response to BNT162b2 Vaccine in Immune Modifiers-Treated Psoriatic Patients

Error in Results and Figure

Erratum to: Transmission risk of patients with COVID-19 meeting discharge criteria should be interpreted with caution (Journal of Zhejiang University-SCIENCE B, (2020), 21, 5, (408-410), 10.1631/jzus.B2000117)

Erratum: Immune-mediated thrombotic thrombocytopenic purpura following mRNA-based COVID-19 vaccine BNT162b2: Case report and mini-review of the literature

Erratum To: Transmission Risk of Patients with COVID-19 Meeting Discharge Criteria Should Be Interpreted with Caution

Correction to "Protecting infants against RSV disease: an impact and cost-effectiveness comparison of long-acting monoclonal antibodies and maternal vaccination" [The Lancet Regional Health - Europe 38 (2024) 100829]

Correction: Corrigendum: the Changing Shape of Vaccination: Improving Immune Responses Through Geometrical Variations of a Microdevice for Immunization

Author Correction: Mucosal vaccine-induced cross-reactive CD8 + T cells protect against SARS-CoV-2 XBB.1.5 respiratory tract infection

Error in Results and Additional Information Section Added to End Matter

Erratum: Epidemiology of Genital Chlamydial Infection in China in 2019: Erratum

Correction: Suleman et al. Immunoinformatics and Immunogenetics-Based Design of Immunogenic Peptides Vaccine against the Emerging Tick-Borne Encephalitis Virus (TBEV) and Its Validation through In Silico Cloning and Immune Simulation. Vaccines 2021, 9, 1210

Interim report of the reactogenicity and immunogenicity of SARS-CoV-2 XBB-containing vaccines

Corrigendum: High-Dose Intravenous Immunoglobulin in Severe Coronavirus Disease 2019: A Multicenter Retrospective Study in China

Corrigendum to 'Impact of COVID-19 on immunocompromised populations during the Omicron era: insights from the observational population-based INFORM study' [The Lancet Regional Health - Europe 35 (2023) 100747]

Correction: Severe COVID-19 infection: An institutional review and literature overview